Logo Image
Opinion|Videos|January 2, 2025

Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024

Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, highlighting its safety profile and 100% minimal residual disease (MRD) negativity after cycle 3, and explores how using bispecific antibodies like teclistamab earlier in treatment could influence future options for relapsed/refractory multiple myeloma.

Episodes in this series

Video content above is prompted by the following:

  • Bispecific antibodies have had a significant impact on the treatment landscape for R/R multiple myeloma. Data presented at ASH is evaluating the use of bispecifics earlier in treatment. Briefly describe the data presented on MajesTEC-5, which evaluates teclistamab in combination with standard therapy in the frontline setting.
  • What was the objective of this study?
  • How was this study designed/what methodology was used?
  • What results were presented?
  • Primary end point: safety
  • Secondary end point: MRD negativity, 100% after cycle 3
  • How might using teclistamab in earlier lines of therapy influence treatment options in the relapsed setting?

Related Content